Sandu Pharmaceuticals Ltd
Incorporated in 1985, Sandu Pharmaceuticals Ltd manufactures and trades Ayurvedic proprietary medicines.
- Market Cap ₹ 50.2 Cr.
- Current Price ₹ 52.0
- High / Low ₹ 69.5 / 43.8
- Stock P/E 32.4
- Book Value ₹ 43.5
- Dividend Yield 1.54 %
- ROCE 5.44 %
- ROE 3.75 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.20 times its book value
Cons
- The company has delivered a poor sales growth of 6.79% over past five years.
- Company has a low return on equity of 3.80% over last 3 years.
- Promoter holding has decreased over last 3 years: -7.53%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
34.52 | 38.17 | 38.86 | 42.82 | 49.02 | 49.42 | 48.37 | 58.76 | 65.50 | 65.35 | 67.28 | 67.19 | |
32.43 | 35.74 | 35.97 | 40.97 | 46.55 | 47.33 | 46.92 | 56.60 | 62.62 | 62.86 | 64.98 | 64.43 | |
Operating Profit | 2.09 | 2.43 | 2.89 | 1.85 | 2.47 | 2.09 | 1.45 | 2.16 | 2.88 | 2.49 | 2.30 | 2.76 |
OPM % | 6.05% | 6.37% | 7.44% | 4.32% | 5.04% | 4.23% | 3.00% | 3.68% | 4.40% | 3.81% | 3.42% | 4.11% |
0.33 | 0.14 | 0.12 | 0.56 | 0.12 | 0.57 | 0.45 | 0.19 | 0.08 | 0.33 | 0.42 | 0.17 | |
Interest | 1.06 | 1.37 | 1.64 | 1.49 | 1.23 | 1.01 | 0.43 | 0.11 | 0.11 | 0.08 | 0.06 | 0.10 |
Depreciation | 0.54 | 0.57 | 0.69 | 0.87 | 0.60 | 0.64 | 0.55 | 0.56 | 0.53 | 0.52 | 0.58 | 0.67 |
Profit before tax | 0.82 | 0.63 | 0.68 | 0.05 | 0.76 | 1.01 | 0.92 | 1.68 | 2.32 | 2.22 | 2.08 | 2.16 |
Tax % | 40.24% | 34.92% | 22.06% | 1,000.00% | 26.32% | 34.65% | 21.74% | 35.12% | 31.47% | 31.08% | 29.33% | 28.24% |
0.50 | 0.41 | 0.54 | -0.44 | 0.56 | 0.67 | 0.72 | 1.09 | 1.59 | 1.52 | 1.46 | 1.55 | |
EPS in Rs | 0.71 | 0.58 | 0.76 | -0.62 | 0.79 | 0.95 | 1.02 | 1.38 | 1.80 | 1.57 | 1.51 | 1.60 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 36.33% | 41.56% | 0.00% | 52.93% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 7% |
3 Years: | 1% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 17% |
3 Years: | -1% |
TTM: | 6% |
Stock Price CAGR | |
---|---|
10 Years: | 8% |
5 Years: | 26% |
3 Years: | -7% |
1 Year: | -13% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 4% |
3 Years: | 4% |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.92 | 8.81 | 9.66 | 9.66 | 9.66 |
Reserves | 11.13 | 11.06 | 11.60 | 20.33 | 21.00 | 21.71 | 22.16 | 25.57 | 27.66 | 29.58 | 30.93 | 32.36 |
9.99 | 12.47 | 11.39 | 10.56 | 9.42 | 6.17 | 1.25 | 0.02 | 0.00 | 0.00 | 0.00 | 0.48 | |
8.67 | 10.91 | 11.33 | 8.46 | 7.03 | 8.67 | 10.92 | 13.45 | 12.81 | 14.92 | 11.83 | 13.22 | |
Total Liabilities | 36.87 | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.72 |
9.09 | 8.36 | 7.81 | 17.49 | 17.57 | 17.04 | 16.60 | 16.17 | 16.00 | 16.62 | 17.88 | 18.15 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 0.42 | 0.00 | 0.00 |
Investments | 0.69 | 0.70 | 0.73 | 0.99 | 1.12 | 1.13 | 0.82 | 0.24 | 9.11 | 9.66 | 10.43 | 11.22 |
27.09 | 32.46 | 32.86 | 27.95 | 25.84 | 25.46 | 23.99 | 30.55 | 23.69 | 27.46 | 24.11 | 26.35 | |
Total Assets | 36.87 | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.72 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1.06 | 4.75 | -1.43 | 4.91 | 1.23 | 3.74 | 6.20 | 7.59 | 0.95 | 0.22 | 0.76 | 0.95 | |
-0.70 | -0.18 | 0.05 | -0.59 | -0.62 | -0.10 | -0.37 | -5.58 | -5.47 | 0.53 | -1.31 | -0.18 | |
-0.25 | -1.90 | -2.06 | -2.33 | -1.89 | -4.26 | -5.36 | 1.30 | 0.93 | 0.58 | -0.72 | -0.46 | |
Net Cash Flow | -2.01 | 2.67 | -3.44 | 1.99 | -1.28 | -0.62 | 0.48 | 3.31 | -3.59 | 1.33 | -1.27 | 0.31 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 62.38 | 62.73 | 67.16 | 54.13 | 49.81 | 35.45 | 35.32 | 33.23 | 22.23 | 26.75 | 26.42 | 25.86 |
Inventory Days | 233.52 | 210.09 | 206.51 | 152.04 | 146.77 | 191.00 | 208.65 | 117.86 | 115.06 | 167.70 | 137.28 | 160.90 |
Days Payable | 76.75 | 103.39 | 100.86 | 58.22 | 38.75 | 60.93 | 83.69 | 70.57 | 69.63 | 98.30 | 46.96 | 51.05 |
Cash Conversion Cycle | 219.16 | 169.43 | 172.82 | 147.94 | 157.84 | 165.52 | 160.28 | 80.52 | 67.67 | 96.15 | 116.75 | 135.70 |
Working Capital Days | 181.97 | 170.59 | 199.13 | 145.34 | 97.99 | 83.90 | 81.50 | 39.63 | 42.41 | 52.33 | 56.75 | 63.12 |
ROCE % | 6.93% | 6.80% | 7.75% | 4.26% | 5.14% | 5.58% | 4.13% | 5.59% | 6.94% | 6.08% | 5.36% | 5.44% |
Documents
Announcements
-
Announcement Under Regulation 30-Response To Discrepancy Related To Delay In Submission Of Information Regarding Intimation In Respect Of The Show Cause Notice Received From Government Of Maharashtra Department Of Goods And Service Tax Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
4 Jun - Show cause notice of Rs.96.48 lakh GST ITC issue; delay in disclosure due to email error.
-
Announcement Under Regulation 30-Intimation In Respect Of The Show Cause Notice Received From Government Of Maharashtra Department Of Goods And Service Tax Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
3 Jun - Received GST show cause notice for Rs.96.48 lakh; company confident of favorable outcome.
-
Intimation Of Submission Of Application For Reclassification Of Person Forming Part Of The 'Promoter Group Category To Public Category' Shareholder Of The Company Pursuant To Regulation 31A Of SEBI (LODR) Regulations, 2015 ('SEBI LODR Regulations').
30 May - Reclassification of Akshath Finvest from Promoter Group to Public category with 5.12% shares.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Newspaper Publication for Audited Financial results for Q and Year ended 31.03.2025
-
Announcement Under Regulation 30
28 May - Approved FY25 audited results; final dividend Rs.0.80/share; appointed secretarial and cost auditors; promoter reclassification.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:[1]
Company manufactures over 100 types of products, including oils, syrups, granules, powder, and avlehas, which are marketed under the Sandu brand viz, Sandu Ashoka Compound, Sandu Abhayarishta, Sandu Arvindasav, Sandu Balant Kadha No. 1, Sandu Debix Tablet, Sandu Bhunimbadi Kadha, Sandu Chandanasav Syrup, Sandu Chandraprabha, Sandu Chyavanprash Special, Sandu Dadimavaleha, etc.